Form 4: Stoke Therapeutics Director Receives Stock Option Grant

Director Adrian R. Krainer was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Adrian R. Krainer received a grant of 17,786 stock options on June 3, 2026.
• The options have an exercise price of $29.46 per share.
• The options are set to expire on June 2, 2036.
• Vesting is scheduled for the earlier of June 3, 2027, or the date of the next annual stockholder meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.
• Vesting is subject to the director's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain scientific and industry expertise for board oversight.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period aligns with common corporate governance practices for board members.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 3, 2027, or the next annual meeting.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Options, Equity Compensation, Biotech